United States securities and exchange commission logo

                          February 1, 2022

       Paul Edick
       Chairman and Chief Executive Officer
       Xeris Biopharma Holdings, Inc.
       180 N. LaSalle Street, Suite 1600
       Chicago, Illinois 60601

                                                        Re: Xeris Biopharma
Holdings, Inc.
Statement on Form S-3
                                                            Filed January 28,
                                                            File No. 333-262403

       Dear Mr. Edick:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Michael
Davis at 202-551-4385 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Joseph C. Theis, Jr.,